If Teva's mystery drug isn't Lipitor, could it be ...?
This article was originally published in Scrip
Executive Summary
Comments made by executives of Teva Pharmaceutical Industries during the third-quarter results call this week have been picked apart by analysts and other observers who claim to have deduced that the company is planning to launch a generic version of Pfizer's Lipitor (atorvastatin) in the US in the next month or so, despite the fact that the 6-month period of generic exclusivity in the US rests with Ranbaxy.